Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04030455 · OUTCOME

To Determine the 2-year Relapse-free Survival (RFS) and Overall Survival (OS) in the Overall Population and in the Subgroup Who Achieves a pCR (RFS)

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer · Source last updated 2026-03-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
proportion of participants
Interval / dispersion
95% Confidence Interval
Time frame
from first study registration to recurrence after local therapy or death from any cause (up to 2 years follow up)

What was measured

Relapse free survival is defined as the time from study registration to recurrence after local therapy or death from any cause. Recurrence was counted only if it occurred after definitive local therapy (surgery and/or radiotherapy). Patients achieving durable complete responses to PCD without local therapy, and patients receiving local therapy without subsequent recurrence, were censored at last follow-up.

Groups in this outcome

Experimental (Cis/Doce/Pembro)

cis 75 mg/m2 (SOC), doce 74 mg/m2 (SOC), pembro 200mg (Exp), Q3W IV

PCR Participants

Out of the experimental group these subjects had pathological complete response

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Experimental (Cis/Doce/Pembro)24
PCR Participants19

Reported measurements

Source class 1
Values in proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Experimental (Cis/Doce/Pembro)0.75Not reported0.580.92Not reported
PCR Participants0.79Not reported0.610.97Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.58
        upper Limit
        0.92
        value
        0.75
      2. group Id
        OG001
        lower Limit
        0.61
        upper Limit
        0.97
        value
        0.79
denoms
  1. counts
    1. group Id
      OG000
      value
      24
    2. group Id
      OG001
      value
      19
    units
    Participants
description
Relapse free survival is defined as the time from study registration to recurrence after local therapy or death from any cause. Recurrence was counted only if it occurred after definitive local therapy (surgery and/or radiotherapy). Patients achieving durable complete responses to PCD without local therapy, and patients receiving local therapy without subsequent recurrence, were censored at last follow-up.
dispersion Type
95% Confidence Interval
groups
  1. description
    cis 75 mg/m2 (SOC), doce 74 mg/m2 (SOC), pembro 200mg (Exp), Q3W IV
    id
    OG000
    title
    Experimental (Cis/Doce/Pembro)
  2. description
    Out of the experimental group these subjects had pathological complete response
    id
    OG001
    title
    PCR Participants
param Type
NUMBER
reporting Status
POSTED
time Frame
from first study registration to recurrence after local therapy or death from any cause (up to 2 years follow up)
title
To Determine the 2-year Relapse-free Survival (RFS) and Overall Survival (OS) in the Overall Population and in the Subgroup Who Achieves a pCR (RFS)
type
SECONDARY
unit Of Measure
proportion of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice